SRA1
Reaktivität: Human
WB, IP
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blot:1:500 - 1:2,000 IHC(P):1:500 - 1:2,000 IHC(F):1:500 - 1:2,000 ELISA:Propose dilution 1:10,000 Determining optimal working dilutions by titration test.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Lagerung
-20 °C
Informationen zur Lagerung
SRA monoclonal antibody can be stored at -20 °C, stable for one year.
Target
SRA1
(Steroid Receptor RNA Activator 1 (SRA1))
Andere Bezeichnung
SRA
Hintergrund
Steroid receptor RNA activator 1 (SRA), with 237-amino acid protein (about 27 kDa), belongs to the growing family of functional non-coding RNAs. SRA was originally described as the first functional noncoding RNA able to specifically coactivate the activity of steroid receptors. Specifically, SRA exists as both an RNA transcript that forms a complex with steroid receptor coactivator-1 and as a stably expressed protein. Its expression is strongly up-regulated in many human tumors of the breast, uterus, and ovary, suggesting a potential role in pathogenesis. Although coactivation of steroid-dependent transcription by SRA is accompanied by a proliferative response, overexpression is not in itself sufficient to induce turmorigenesis.